Erratum: Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

, Frontiers Production Office

doi:10.3389/fonc.2022.920342

ERRATUM article

Front. Oncol. , 04 May 2022

Sec. Cancer Genetics

Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.920342

Erratum: Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

This article is an erratum on:

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
1. Read original article

Frontiers Production Office^*

Frontiers Media SA, Lausanne, Switzerland

An Erratum on:
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

By Fanale D, Fiorino A, Incorvaia L, Dimino A, Filorizzo C, Bono M, Cancelliere D, Calò V, Brando C, Corsini LR, Sciacchitano R, Magrin L, Pivetti A, Pedone E, Madonia G, Cucinella A, Badalamenti G, Russo A and Bazan V (2021). Front. Oncol. 11:682445. doi: 10.3389/fonc.2021.682445

Due to a production error, there was a mistake in Table 2 as published. Some BRCA1 variants were incorrectly listed. The correct Table 2 appears below. The publisher apologizes for this mistake.

TABLE 2

Table 2 BRCA1 gene variants of unclear significance harbored by patients with breast and ovarian cancers.

The original version of this article has been updated.

Keywords: BRCA1, BRCA2, breast cancer, genetic testing, ovarian cancer, variants of uncertain significance (VUS)

Citation: Frontiers Production Office (2022) Erratum: Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome. Front. Oncol. 12:920342. doi: 10.3389/fonc.2022.920342

Received: 14 April 2022; Accepted: 14 April 2022;
Published: 04 May 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Erratum: Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

95% of researchers rate our articles as excellent or good

95% of researchers rate our articles as excellent or good